Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Leask

Showing results (51-60 of 221) with videos related to

Pageof 23
Sort By:
Journal of Cell Communication and Signaling|January 15, 2011
Targeting the jagged/notch pathway: a new treatment for fibrosis?Andrew Leask
Journal of Cell Communication and Signaling|January 15, 2011
CCN6 (WISP3): a new anti-cancer therapy?Andrew Leask
Journal of Cell Communication and Signaling|June 10, 2010
It's a knockout: CCN3 suppresses neointimal thickeningAndrew Leask
Frontiers in Bioscience (Elite Edition)|June 2, 2009
Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in sclerodermaAndrew Leask
Journal of Cell Communication and Signaling|November 14, 2016
CCN3: stopping that achy, breaky aortaAndrew Leask
Advances in Wound Care|February 15, 2014
Focal Adhesion Kinase: A Key Mediator of Transforming Growth Factor Beta Signaling in FibroblastsAndrew Leask
Cellular Signalling|February 26, 2008
Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in sclerodermaAndrew Leask
Arthritis Research & Therapy|June 16, 2006
Scar wars: is TGFbeta the phantom menace in scleroderma?Andrew Leask
Cardiovascular Research|August 22, 2006
TGFbeta, cardiac fibroblasts, and the fibrotic responseAndrew Leask
Journal of Cell Communication and Signaling|July 22, 2021
Yay team!: 5.782Andrew Leask
Pageof 23

Showing results (51-60 of 221) with videos related to

Sort By:
Pageof 23
Journal of Cell Communication and Signaling|January 15, 2011
Targeting the jagged/notch pathway: a new treatment for fibrosis?Andrew Leask
Journal of Cell Communication and Signaling|January 15, 2011
CCN6 (WISP3): a new anti-cancer therapy?Andrew Leask
Journal of Cell Communication and Signaling|June 10, 2010
It's a knockout: CCN3 suppresses neointimal thickeningAndrew Leask
Frontiers in Bioscience (Elite Edition)|June 2, 2009
Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in sclerodermaAndrew Leask
Journal of Cell Communication and Signaling|November 14, 2016
CCN3: stopping that achy, breaky aortaAndrew Leask
Advances in Wound Care|February 15, 2014
Focal Adhesion Kinase: A Key Mediator of Transforming Growth Factor Beta Signaling in FibroblastsAndrew Leask
Cellular Signalling|February 26, 2008
Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in sclerodermaAndrew Leask
Arthritis Research & Therapy|June 16, 2006
Scar wars: is TGFbeta the phantom menace in scleroderma?Andrew Leask
Cardiovascular Research|August 22, 2006
TGFbeta, cardiac fibroblasts, and the fibrotic responseAndrew Leask
Journal of Cell Communication and Signaling|July 22, 2021
Yay team!: 5.782Andrew Leask
Pageof 23